Group 1: Company Overview - Assertio (ASRT) is a specialty pharmaceutical company focused on branded prescription medications for neurology, inflammation, and pain [1] - Bridgeline Digital (BLIN) operates as a digital engagement company, offering a platform that integrates Web Content Management, e-commerce, e-marketing, Social Media management, and Web Analytics [2] - Booz Allen Hamilton (BAH) provides management and technology consulting, analytics, engineering, digital solutions, mission operations, and cyber expertise to governments, corporations, and not-for-profit organizations [3] Group 2: Earnings Estimates - The Zacks Consensus Estimate for Assertio's current year earnings has been revised downward by 83.3% over the last 60 days [1] - Bridgeline Digital's current year earnings estimate has been revised downward by almost 47.1% over the last 60 days [2] - Booz Allen Hamilton's current year earnings estimate has been revised downward by 6.8% over the last 60 days [3]

THE ALLEGED WRONGDOING: On June 10, 2025, PetMed announced that it would delay the release of its fourth-quarter and full-year 2025 earnings due to the company's need for additional time to complete its year-end audit process. On this news, PetMed's stock price fell $0.47, or 11.2%, to close at $3.72 per share on June 11, 2025 Then, on July 1, 2025, PetMed announced it would delay filing its annual report with the SEC amid an internal investigation conducted by the company's Audit Committee. PetMed attribut ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following Novo Nordisk's announcement on June 23, 2025, to terminate its partnership with Hims & Hers due to these deceptive practices, Hims & Hers' stock price dropped by over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, primarily related to misleading statements and the promotion of illegitimate products, which led to a significant drop in stock price following the termination of a partnership with Novo Nordisk [1][2]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - Following the allegations, Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason [2]. - The lawsuit claims that the stock price of Hims & Hers fell by more than 34% after the announcement of the partnership termination [2]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [3]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [3]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [4]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [4].

SAN DIEGO, June 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Hims & Hers Health, Inc. (NYSE: HIMS) focused on whether Hims & Hers and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Hims & Hers investigation or if you are a Hims & Hers investor who suffered a loss and would like to learn ...